Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome Combined With Anlotinib for Recurrent Small Cell Lung Cancer
NCT06258642Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome injection in small cell lung cancer (SCLC), sponsored by Fudan University. Started Apr 2024; status: recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06258642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258642.